Personalized medicine—the adaptation of therapies based on an individual's genetic and
molecular profile—is one of the most promising aspects of modern medicine. The …

While antidepressants are widely used to treat mood and anxiety disorders, only half of the
patients will respond to antidepressant treatment and only one-third of patients experience a …

While antidepressant pharmacotherapy is an effective treatment of depression, it is still
hampered by the slow onset of appreciable clinical improvement and a series of side effects …

There is substantial interindividual variation in response to antidepressants. Family and twin
studies suggest that genetic variation may, at least in part, explain these differences …

The past few decades have witnessed much progress in the field of pharmacogenetics. The
identification of the genetic background that regulates the antidepressant response has …

Major depressive disorder (MDD) is an emergent cause of personal and socio‐economic
burden, both for the high prevalence of the disorder and the unsatisfying response rate of …

More than fifty years of pharmacogenetic research have produced many examples of the
impact of inherited variability in the response to psychotropic drugs. These successes …

Objective: Major depressive disorder is the most common psychiatric disorder, worldwide,
yet response and remission rates are still unsatisfactory. The identification of genetic …

Genetic factors contribute to the phenotype of drug response. We systematically analyzed all
available pharmacogenetic data from Medline databases (1970–2003) on the impact that …

BACKGROUND: Pharmacogenetic studies aiming to personalize the treatment of
depression are based on the assumption that response to antidepressants is a heritable …